Wednesday, 14 October 2026European Markets

VIRBAC Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with virbac (virp.pa) jumping 10.69% to €336.50 on tuesday while cac 40 jumped 0.08% to €7,574.67.

virbac's last close was €304.00, 3.18% below its 52-week high of €314.00.

about virbac

virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.

earnings per share

as for profitability, virbac has a trailing twelve months eps of €14.14.

pe ratio

virbac has a trailing twelve months price to earnings ratio of 23.8. meaning, the purchaser of the share is investing €23.8 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.8%.

revenue growth

year-on-year quarterly revenue growth declined by 1%, now sitting on 1.21b for the twelve trailing months.

yearly top and bottom value

virbac's stock is valued at €336.50 at 21:36 est, higher than its 52-week high of €314.00.

dividend yield

according to morningstar, inc., the next dividend payment is on jun 26, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.49%.

volume

today's last reported volume for virbac is 9081 which is 63.09% above its average volume of 5568.

more news about virbac (virp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com